ICU Medical, Inc. (ICUI)

収益の仕組み

Most of the money comes from selling physical products that get thrown away after one use. The pumps and monitors are durable equipment sold or placed with hospitals, but each pump then consumes ICU Medical's own dedicated sets, cassettes and connectors for the rest of its life, so the installed base of hardware pulls a recurring stream of consumable orders behind it. Sales are made both directly to hospitals and through wholesalers and distributors, typically under multi-year supply agreements and group purchasing contracts; software such as MedNet and PharmGuard is sold alongside the devices rather than as a standalone subscription business. A small amount of contract manufacturing revenue ($19.0 million in 2025) sits inside Vital Care following the IV Solutions disposal.

セグメント別売上高

A hospital that standardises on Plum or CADD pumps buys the matching administration sets and cassettes for as long as it keeps the fleet, trains its nurses on MedNet drug libraries, and writes those products into its pharmacy workflows; changing supplier means recapitalising the pumps and retraining staff, which is slow and expensive. Around this sit long-standing group purchasing and supply contracts and a patent estate on the Clave connector family. The advantage is real but bounded: the company itself lists competition from larger global players and healthcare cost-containment pressure among its risk factors, and hospital contracts do come up for renewal.

Most of what ICU Medical sells is consumed by treatments that happen whether or not the economy is doing well: infusions, chemotherapy, surgery, intensive care. Volumes track hospital patient activity, the number of procedures, and long-run drivers such as an ageing population and infection-control rules, not the business cycle. The cyclical part sits in the capital equipment: when hospital budgets tighten, a pump fleet replacement can be postponed a year, which pushes out Infusion Systems orders while the consumable stream keeps running. Government and insurer cost-containment, which the company lists as a risk factor, is a steadier pressure on price than any recession.

主なリスク

• Competition and pricing pressure from healthcare cost containment — The company states that an inability to compete successfully could cost it market share and profitability, and that efforts by governments, insurers and hospitals to contain healthcare costs reduce both the prices it can charge and the volumes demanded.
• Dependence on a small number of distributors — A significant share of sales passes through distributors, and the 10-K discloses worldwide net sales to a single distributor equal to 18% of consolidated net sales in 2025 (18% in 2024, 16% in 2023). Losing or disrupting such a relationship is flagged as a material operational and financial exposure.
• FDA quality-system and regulatory compliance — Failure to meet FDA Quality Management System or manufacturing requirements could interrupt operations and hit sales; separately, the company notes that staffing or funding gaps at the agency itself may delay clearances and slow the commercialisation of new products.
• Manufacturing concentration and single-source suppliers — Damage to a facility or a business interruption at a supplier would impair the ability to produce, and the company relies on single- or limited-source suppliers for certain components, so one supplier's failure can stop a product line.
• Trade policy and tariffs — Changes in U.S. trade policy, specifically tariffs affecting Mexico and Costa Rica where the company manufactures, are disclosed as capable of materially harming operations and costs.
• Smiths Medical integration and the debt taken on to buy it — The company discloses that failure to integrate the Smiths Medical acquisition successfully could damage its reputation and performance, and that the substantial debt raised to fund it restricts financial flexibility and its ability to pursue future transactions.
• Cybersecurity, IT failure and data privacy — Data breaches or IT system failures could disrupt operations and create liability, and violations of privacy and security laws governing patient data could harm operations and reputation.
• Intellectual property — Patent infringement claims, the cost of defending them, and the expiry of existing patents are all disclosed as threats to the company's competitive position.
• Anti-kickback and false claims laws — Non-compliance with the Anti-Kickback Statute and false claims legislation exposes the company to investigations and penalties.
• Macroeconomic conditions and currency — Inflation, interest rates and foreign exchange volatility are disclosed as headwinds; with operations in over 100 countries, exchange-rate swings can adversely affect international results.
• Recovering investment in equipment, tooling and R&D — A significant fall in demand could leave the company unable to recover the substantial sums sunk into equipment and tooling, and the high cost of developing new products may prove hard to fund and to recoup commercially.
• Execution of cost-reduction programmes — The restructuring and cost-reduction work under way may not deliver the efficiencies or the profitability improvement the company expects.

主要顧客が売上高の18%を占める

The 10-K discloses worldwide net sales to a single distributor equal to 18% of consolidated net sales in 2025, the same as in 2024 and up from 16% in 2023. The company does not break out a combined top-customers figure, so 18% is the only concentration number the filing states. Underlying end demand is spread across acute-care hospitals, clinics and alternate-site facilities in more than 100 countries, but a large slice of it reaches them through that one distribution relationship, which the company names as a risk factor in its own right.